论文部分内容阅读
选取2012年10月至2014年12月在云南省曲靖市第二医院内分泌科门诊就诊及住院的超重和肥胖2型糖尿病患者36例,以往应用口服降糖药物或胰岛素治疗血糖控制不能达标,即糖化血红蛋白(Hb A1c)﹥7.0%,按BMI分为A组(超重组,24~28 kg/m2)18例、(肥胖组,BMI≥28 kg/m2)18例,两组均加用利拉鲁肽。治疗12周。结果两组患者Hb A1c、FBG、2 h PG、胰岛B细胞功能指数(HOMA-B)=(2h Ins-Fins)/(2h PG-FPG)、胰岛素抵抗指数(Homa-IR)=FPG×Fins/22.5与治疗前相比均降低(P<0.01)。上述指标治疗后组间比较无明显差异性(P>0.05)。治疗后B组体重较对照组体重下降明显(P<0.01)。结论超重和肥胖2型糖尿病患者,加用利拉鲁肽注射液治疗后,能有效地控制血糖,改善胰岛素抵抗及胰岛素敏感性,而肥胖患者体重下降显著,疗效更佳。
Thirty-six patients with overweight and obesity type 2 diabetes who were admitted to the Department of Endocrinology, the Second Hospital of Qujing City, Yunnan Province from October 2012 to December 2014 were selected. In the past, oral glucose-lowering drugs or insulin therapy could not control blood sugar level, According to BMI, 18 cases were divided into group A (overweight group, 24-28 kg / m2), 18 cases (obesity group, BMI≥28 kg / m2), and both groups were treated with Hb A1c Lalupeptide. Treatment for 12 weeks. Results Hb A1c, FBG, 2 h PG, HOMA-B (2h Ins-Fins) / (2h PG-FPG), Homa-IR = FPG × Fins /22.5was lower than before treatment (P <0.01). There was no significant difference between the above groups after treatment (P> 0.05). After treatment, the weight of group B was significantly lower than that of control group (P <0.01). Conclusion Overweight and obese type 2 diabetic patients treated with liraglutide injection can effectively control blood sugar and improve insulin resistance and insulin sensitivity. Obesity patients with significant weight loss and better efficacy.